Vi­a­tris tar­gets ul­cer­a­tive col­i­tis in Japan with $10M agree­ment with Swedish phar­ma In­Dex

Vi­a­tris is go­ing af­ter the ul­cer­a­tive col­i­tis mar­ket in Japan, ink­ing a li­cens­ing agree­ment with Swe­den’s In­Dex Phar­ma­ceu­ti­cals to reg­is­ter and com­mer­cial­ize co­bitolimod, a TLR9 ag­o­nist.

Vi­a­tris will pay In­Dex an up­front fee of $10 mil­lion for the ex­clu­sive rights to the drug in Japan for mod­er­ate to se­vere ul­cer­a­tive col­i­tis. In­Dex is al­so el­i­gi­ble to re­ceive de­vel­op­ment and sales mile­stone pay­ments of up to $40 mil­lion. Vi­a­tris will al­so pay up to dou­ble-dig­it per­cent­age roy­al­ties based on net sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER